CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects.

Clin Diagn Lab Immunol. 2000 Mar;7(2):279-87. Unique Identifier : AIDSLINE MED/20169431
Huang XL; Fan Z; Kalinyak C; Mellors JW; Rinaldo CR Jr; University of Pittsburgh Graduate School of Public Health,; Pittsburgh, Pennsylvania 15261, USA.

Abstract: The CD8(+)-T-cell response to human immunodeficiency virus type 1 (HIV-1) is considered to be important in host control of infection and prevention of AIDS. We have developed a single-cell enzyme immunoassay (enzyme-linked immunospot assay) specific for gamma interferon (IFN-gamma) production stimulated by either autologous B-lymphoblastoid cell lines (B-LCL) infected with vaccinia virus vectors expressing HIV-1 proteins or synthetic peptides representing known HIV-1 CD8(+) cytotoxic T-lymphocyte (CTL) epitopes. Single-cell IFN-gamma production stimulated by HIV-1 Gag-, Pol-, and Env-expressing B-LCL was a reliable measure of HIV-1-specific T-cell immunity in peripheral blood CD8(+) T cells from HIV-1 infected individuals. This method was more sensitive than stimulation of IFN-gamma by direct infection of the cultures with HIV-1-vaccinia virus vectors. Comparable results were found for IFN-gamma production in CD8(+) T cells from HIV-1-negative, cytomegalovirus (CMV)-seropositive, healthy donors stimulated with B-LCL expressing the CMV pp65 lower matrix protein. HIV-1 peptides were immunodominant for both CD8(+) single-cell IFN-gamma production and CTL precursor frequencies. The number of cells producing IFN-gamma decreased in individuals with late-stage HIV-1 infection and was temporally enhanced during combination antiretroviral therapy with two reverse transcriptase nucleoside inhibitors and a protease inhibitor.

Keywords: JOURNAL ARTICLE Cells, Cultured Cryopreservation CD8-Positive T-Lymphocytes/*IMMUNOLOGY/VIROLOGY Gene Products, env/IMMUNOLOGY Gene Products, gag/IMMUNOLOGY Gene Products, pol/IMMUNOLOGY Genetic Vectors/GENETICS Histocompatibility Antigens Class I/IMMUNOLOGY Histocompatibility Antigens Class II/IMMUNOLOGY Human HIV Antigens/IMMUNOLOGY HIV Infections/BLOOD/*IMMUNOLOGY HIV-1/GENETICS/*IMMUNOLOGY Immunophenotyping Interferon Type II/*BIOSYNTHESIS Leukocytes, Mononuclear/IMMUNOLOGY Male Peptides/IMMUNOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocytes, Cytotoxic/IMMUNOLOGY Vaccinia Virus/GENETICS
000730
A0071448

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .